BerGenBio Salute del bilancio

Salute finanziaria criteri di controllo 5/6

BerGenBio ha un patrimonio netto totale di NOK153.4M e un debito totale di NOK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente NOK194.7M e NOK41.4M.

Informazioni chiave

Rapporto debito/patrimonio netto

NOK 0

Debito

Indice di copertura degli interessi	n/a
Contanti	NOK 174.84m
Patrimonio netto	NOK 153.38m
Totale passività	NOK 41.36m
Totale attività	NOK 194.74m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Sep 21

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Jun 02

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Aug 24

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Feb 06

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Sep 26

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Jun 11

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Feb 17

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

Sep 21

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NOK194.6M ) di BGBIO superano le sue passività a breve termine ( NOK41.4M ).

Passività a lungo termine: BGBIO non ha passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: BGBIO è esente da debiti.

Riduzione del debito: BGBIO non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 0.02%.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: BGBIO ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: BGBIO ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 3.6 % ogni anno

BerGenBio Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Recent updates

BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024

New major risk - Share price stability

Martin Olin to Step Down from BerGenBio ASA as CEO

BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Price target decreased by 63% to kr5.68

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

Chief Executive Officer exercised options to buy kr323k worth of stock.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

Price target decreased to kr12.00

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

BerGenBio ASA Provides Update on Clinical Development

Chairman of the Board recently bought kr268k worth of stock

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to kr47.50

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Chief Executive Officer recently bought kr204k worth of stock

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

New 90-day low: kr30.75

Analysts update estimates

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Revenue and earnings in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

Price target raised to kr63.00

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

New 90-day high: kr37.30

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

New 90-day high: kr36.00

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020